Literature DB >> 19602898

Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin.

I S Elefsiniotis1, E Vezali, C Mihas, G Saroglou.   

Abstract

OBJECTIVES: To investigate early viral kinetics, sustained virological response (SVR) rates and their predictors, in treatment-naïve, genotype-4-infected, chronic hepatitis C (CHC) patients treated with PEG-IFNalpha2b plus ribavirin. PATIENTS AND METHODS: In total, 58 patients were retrospectively analyzed. Early virological response (EVR) was defined as undetectable HCV-RNA (<50 IU/ml) at week 12 (complete, cEVR) or at least a 2 log decrease in HCV-RNA levels (partial, pEVR).
RESULTS: Thirty-one patients exhibited SVR (53.4%), 17 (29.3%) were non-responders and 10 (17.2%) relapsed. Thirty-seven patients (63.8%) exhibited EVR. The positive predictive values of EVR, cEVR and pEVR for the SVR achievement were 83.87, 54.83, and 29.03%, whereas their negative predictive values were 59.25, 77.77, and 81.48%, respectively. Both cEVR (OR 0.040, p = 0.042) and EVR (OR 0.016, p = 0.006) independently predicted SVR. Baseline viral load (p < 0.001), age (p = 0.035) and stage of liver disease (p = 0.04) were significantly related to the EVR achievement, whereas only baseline viral load (p = 0.003) and ethnicity (p = 0.025) predicted cEVR.
CONCLUSIONS: Partial or complete EVR represent independent predictors of SVR in genotype-4-infected CHC patients, regardless of their baseline parameters. The absence of pEVR, rather than the absence of cEVR, should be used as an early indication for discontinuation of treatment in these patients. Copyright (c) 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19602898     DOI: 10.1159/000228548

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  6 in total

1.  Meta-analysis: influence of host and viral factors in patients with chronic hepatitis C genotype 4 treated with pegylated interferon and ribavirin.

Authors:  Brittany E Yee; Nghia H Nguyen; Bing Zhang; Philip Vutien; Carrie R Wong; Glen A Lutchman; Mindie H Nguyen
Journal:  Eur J Gastroenterol Hepatol       Date:  2014-11       Impact factor: 2.566

2.  Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNalpha2a shows earlier viral decline than peg-IFNalpha2b in combination therapy with ribavirin.

Authors:  Tatsuya Fujino; Makoto Nakamuta; Yoko Aoyagi; Motoyuki Kohjima; Takeaki Satoh; Mika Fukuda; Hiromi Ishibashi; Hiroshi Yatsuhashi; Munechika Enjoji
Journal:  Med Sci Monit       Date:  2011-12

3.  Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients.

Authors:  Giulia Marchetti; Paola Nasta; Francesca Bai; Francesca Gatti; Giusi Maria Bellistrì; Camilla Tincati; Federica Borghi; Giampiero Carosi; Massimo Puoti; Antonella d'Arminio Monforte
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

4.  Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis.

Authors:  Brittany E Yee; Nghia H Nguyen; Bing Zhang; Derek Lin; Philip Vutien; Carrie R Wong; Glen A Lutchman; Mindie H Nguyen
Journal:  BMJ Open Gastroenterol       Date:  2015-07-09

5.  Prediction of treatment week eight response & sustained virologic response in patients treated with boceprevir plus peginterferon alfa and ribavirin.

Authors:  Alex Thompson; Scott Devine; Mike Kattan; Andrew Muir
Journal:  PLoS One       Date:  2014-08-01       Impact factor: 3.240

6.  Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients.

Authors:  Gouda Kamel Helal; Magdy Abdelmawgoud Gad; Mohamed Fahmy Abd-Ellah; Mahmoud Saied Eid
Journal:  J Med Virol       Date:  2016-05-25       Impact factor: 2.327

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.